MEDX ... anybody following? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following?

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (734)	9/9/2003 9:48:41 AM
From: Icebrg	Read Replies (1) of 2240

Medarex presentation at Bear Stearns The most (and perhaps only) noteworthy thing said at the conference was that DD saw the start of a pivotal trial for MDX-010 in refractory multiple myeloma. This should be expected towards the end of this year or early next year. The only thing preventing them from pushing the start-button is (according to DD) that they still have not figured out what the ideal dosing schedule should look like. Not terribly confidence-boosting if you ask me. Evidently they have to find a dosing scheme that will prevent the occurrence of serious auto-immune side-effects, while still producing response data that are good enough for approval. Anyhow, the MDX-010 trials in multiple myeloma speed along. If they can repeat the data presented at ASCO for a larger group of patients the green light from FDA should be a formality. Let's hope they are able to figure out what they should do about the dosing schedule. Erik

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next